Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CASINASDAQ:ENLVNASDAQ:FNCHNASDAQ:FRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCASICASI Pharmaceuticals$1.84+2.8%$1.92$1.64▼$7.67$22.63M0.6695,062 shs3.84 million shsENLVEnlivex Therapeutics$0.91-3.7%$0.96$0.81▼$1.76$21.40M0.74127,327 shs21,988 shsFNCHFinch Therapeutics Group$13.75+6.8%$13.11$1.10▼$15.85$22.08M1.252,186 shs402 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCASICASI Pharmaceuticals-2.13%-4.28%-3.76%-18.78%-44.41%ENLVEnlivex Therapeutics-0.21%+2.17%-6.00%-22.95%-32.37%FNCHFinch Therapeutics Group-5.99%-4.94%-2.20%-5.64%+861.19%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%-2.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCASICASI Pharmaceuticals4.4004 of 5 stars3.53.00.04.33.81.70.6ENLVEnlivex Therapeutics3.4729 of 5 stars3.75.00.00.02.50.81.3FNCHFinch Therapeutics Group0.3601 of 5 stars0.03.00.00.00.01.70.6FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCASICASI Pharmaceuticals 3.00Buy$4.00117.39% UpsideENLVEnlivex Therapeutics 3.33Buy$10.001,004.97% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FRTX, ENLV, CASI, and FNCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/9/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.004/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/24/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCASICASI Pharmaceuticals$31.37M0.72N/AN/A$1.81 per share1.02ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AFNCHFinch Therapeutics Group$110K200.75N/AN/A$14.25 per share0.96FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCASICASI Pharmaceuticals-$26.94M-$2.55N/A∞N/A-143.18%-181.52%-45.72%8/15/2025 (Estimated)ENLVEnlivex Therapeutics-$29.07M-$0.66N/AN/AN/AN/A-67.57%-58.45%6/13/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ALatest FRTX, ENLV, CASI, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q4 2024ENLVEnlivex Therapeutics-$0.16N/AN/AN/AN/AN/A5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/16/2025Q1 2025CASICASI Pharmaceuticals-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million3/31/2025Q4 2024CASICASI Pharmaceuticals-$0.60-$0.79-$0.19-$0.79$7.39 million$13.36 million3/31/2025Q4 2024ENLVEnlivex Therapeutics-$0.16-$0.23-$0.07-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCASICASI PharmaceuticalsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCASICASI Pharmaceuticals1.383.202.32ENLVEnlivex TherapeuticsN/A9.719.71FNCHFinch Therapeutics GroupN/A3.873.87FRTXFresh Tracks TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCASICASI Pharmaceuticals22.23%ENLVEnlivex Therapeutics1.02%FNCHFinch Therapeutics Group21.77%FRTXFresh Tracks Therapeutics25.04%Insider OwnershipCompanyInsider OwnershipCASICASI Pharmaceuticals21.24%ENLVEnlivex Therapeutics12.28%FNCHFinch Therapeutics Group44.90%FRTXFresh Tracks Therapeutics0.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCASICASI Pharmaceuticals18012.30 million12.20 millionOptionableENLVEnlivex Therapeutics7023.65 million18.78 millionOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableFRTX, ENLV, CASI, and FNCH HeadlinesRecent News About These CompaniesFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 26, 2025 | finance.yahoo.comFresh Tracks to cease stock trading as drug company dissolvesFebruary 26, 2025 | bizwest.comFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 25, 2025 | prnewswire.comFresh Tracks Therapeutics Announces Appointment of Custodian and Planned DistributionJanuary 27, 2025 | finance.yahoo.comFresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of CompanyDecember 6, 2024 | prnewswire.comFresh Tracks Therapeutics (OTC:FRTX) Stock, Short Interest ReportOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics (OTC:FRTX) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics Inc (FRTX)August 31, 2024 | uk.investing.comAjofé Drops “One Time,” a Timeless Track with a Fresh BeatAugust 30, 2024 | thisdaylive.comFresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of CompanyJune 17, 2024 | globenewswire.comFresh Tracks Therapeutics Inc. (FRTX) Institutional HoldingsMay 25, 2024 | nasdaq.comExploration capital buys fresh tracks therapeutics shares worth over $19kApril 25, 2024 | investing.comExploration capital purchases Fresh Tracks Therapeutics stock worth $2,805April 13, 2024 | investing.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 16, 2024 | finanznachrichten.deFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | finance.yahoo.comFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | globenewswire.comFresh Tracks Therapeutics IncJanuary 3, 2024 | morningstar.comFresh Tracks leaders doubt they have support for liquidationDecember 28, 2023 | bizwest.comFresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15thDecember 27, 2023 | finance.yahoo.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Announces Listing on OTC Pink MarketDecember 20, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t BudgeFRTX, ENLV, CASI, and FNCH Company DescriptionsCASI Pharmaceuticals NASDAQ:CASI$1.84 +0.05 (+2.79%) Closing price 04:00 PM EasternExtended Trading$1.77 -0.07 (-3.80%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Enlivex Therapeutics NASDAQ:ENLV$0.90 -0.04 (-3.72%) Closing price 03:58 PM EasternExtended Trading$0.91 +0.01 (+0.88%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Finch Therapeutics Group NASDAQ:FNCH$13.75 +0.87 (+6.75%) As of 03:35 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
